The Lamira Nebuliser System is a device from PARI's eFlow® Technology platform that is specifically optimised for the nebulisation of Insmed's ARIKAYCE liposomal 590 mg nebuliser dispersion. Its design allows patients to take their inhalation treatment in the shortest possible nebulisation time1 by normal breathing. For detailed information about ARIKAYCE liposomal refer to the package leaflet of the medicine.
Intended purpose
The Lamira Nebuliser System is intended to administer ARIKAYCE liposomal 590 mg nebuliser dispersion as an aerosol for inhalation.
Indication
The Lamira Nebuliser System is indicated to deliver ARIKAYCE liposomal for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC) in adults. For the indication of ARIKAYCE liposomal refer to the package leaflet of the medicine.
Austria
Phone: 0800-017-825
Belgium
Phone: 0800-79-950
Denmark
Phone: 808-30-340
France
Phone Office: +33 (0)1 40 79 64 37 (available 24/7)
Phone Medical Information: 0805-119-608 (available 24/7)
Germany
Phone: 0800-8888-826
Ireland
Phone: 1800-849-022
Italy
Phone: 800-743-054
Netherlands
Phone: 0800-678-9001
Norway
Phone: 800-25315
United Kingdom
Phone: 0800-0318440
Switzerland
Phone: 0800-892-061
Ελλάδα
Phone: 00-800-325-2726
ARIKAYCE liposomal product information is available on the official website of the European Medicines Agency.
Insmed Netherlands B.V.
Stadsplateau 7
3521 AZ Utrecht
Netherlands
Phone: 00 800 70 50 30 50
ARIKAYCE® is a registered trademark of Insmed Incorporated
eFlow® and Lamira® are registered trademarks of PARI Pharma GmbH
1Treatment should take about 14 minutes but could take up to 20 minutes.
© 2024 PARI GmbH Spezialisten für effektive Inhalation
